New approaches for cancer immunotherapy

Karlıtepe, Ayfer; Ozalp, Ozgun; Avci, Çığır Biray

doi:10.1007/s13277-015-3491-2

Cited by 33 publications

(26 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Personalized vaccines. So far, many vaccination approaches, including immune cell– or dendritic cell–based, tumor cell–based, oncolytic viruses, nanocarrier-delivered, and DNA-based vaccines, have been developed 20, 21 . These treatments can be administered to patients to induce host immunity against specific tumor antigens.…”

Section: Immunotherapy In Cancer: the Most Promising Approachesmentioning

confidence: 99%

Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies

Liotti¹,

Prevete²,

Vecchio³

et al. 2019

F1000Res

View full text Add to dashboard Cite

Tumors modulate the host immune cells within their microenvironment to avoid recognition and elimination by our immune system, a phenotype called cancer immune escape. Different mechanisms responsible for cancer immune escape that result either in decreased tumor immunogenicity or in increased tumor immunosuppressive activity have been identified. Recently, various immunotherapeutic approaches have been developed with the aim to revert tumor immune escape. The aims of this review are to explore the immunological aspects of thyroid cancer and to assess whether these features can be exploited in the prognosis and treatment of advanced forms of this disease. Therefore, we will describe the immune landscape and phenotypes of thyroid cancer, summarize studies investigating the expression of immunomodulatory molecules, and finally describe the preclinical and clinical trials investigating the utility of immunotherapies in the management of thyroid cancer. The aim of this review is to explore the immunological aspects of thyroid cancer and to assess whether these features can be exploited in the prognosis and treatment of advanced forms of this disease. Therefore, we will describe the immune-landscape and phenotypes of thyroid cancer, we will summarize studies investigating the expression of immunomodulatory molecules, and we will finally describe the preclinical and clinical trials investigating the utility of immunotherapies in the management of thyroid cancer.

show abstract

Section: Immunotherapy In Cancer: the Most Promising Approachesmentioning

confidence: 99%

Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies

Liotti¹,

Prevete²,

Vecchio³

et al. 2019

F1000Res

View full text Add to dashboard Cite

show abstract

“…The current strategies consist of cancer vaccines as active immunization, monoclonal antibodies as passive immunization, and cellular therapies that often include lymphocytes and dendritic cells. Cancer vaccines may be effective at preventing cancer by attacking various tumor cells, inducing an immune response (75).…”

Section: Immunotherapy For Pancreatic Cscsmentioning

confidence: 99%

Pancreatic Cancer Stem Cells and Therapeutic Approaches

Ercan

Karlıtepe

Özpolat³

2017

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is considered one of the deadliest human cancers, with 1-5% 5-year survival rates (~6-month median survival duration) despite therapy; thus, PDAC represents an unmet therapeutic challenge. PDAC is the major histological subtype, comprising 90% of all pancreatic cancers. It is a highly complex and aggressive malignancy, presenting with early local invasion and metastasis, and is resistant to most therapies, all of which are believed to contribute to its extremely poor prognosis. PDAC is characterized by molecular alterations, including mutations of K-RAS (~90% of cases), TP53, transforming growth factor-β, Hedgehog, WNT and NOTCH signaling pathways. Given that cancer stem cells have a crucial role not only in tumor initiation and progression, but also in drug resistance and relapse or recurrence of various cancer types, they may be excellent targets for effective novel therapeutic approaches. Here, we reviewed recent therapeutic strategies targeting pancreatic cancer stem cells using chemotherapeutics and targeted drugs, non-coding RNAs (i.e., siRNA and miRNAs), immunotherapy, and natural compounds.

show abstract

“…Furthermore, combined immunotherapy with nivolumab and ipilimumab results in a higher response rate and a longer progression time compared with the action of ipilimumab alone [9]. Considering the success of immune checkpoint inhibitors, these agents may represent a basic component of a therapeutic strategy using checkpoint inhibitors in combination or with other anticancer agents [10,11]. However, when therapeutic strategies use a combination of drugs, toxicity could be a limiting factor.…”

Section: Introductionmentioning

confidence: 99%